[Resection strategies for adrenocortical carcinoma]
- PMID: 30159583
- DOI: 10.1007/s00104-018-0712-4
[Resection strategies for adrenocortical carcinoma]
Abstract
Adrenocortical carcinomas (ACC) are rare and aggressive neoplasms. Due to their high rate of local recurrence and distant metastases (up to 85%) they are associated with a poor survival. The 5‑year survival in ACC patients with lymph node metastasis or local infiltration is 50% and with distant metastasis less than 15%. An R0 resection with locoregional and para-aortic/paracaval lymphadenectomy is the only curative option and reasonable treatment possibility. The treatment of these patients should therefore be planned and carried out in centers. Local recurrences and distant metastases should also be treated with R0 resection when feasible, combined with neoadjuvant/adjuvant chemotherapy and/or radiation. In the case of an asymptomatic non-resectable ACC, debulking operations cannot be recommended. The primary operation can also be done in a minimally invasive procedure if principles of oncological surgery are followed (radical resection, no damage of the tumor capsule, lymphadenectomy), since survival after open and minimally invasive laparoscopic resection was comparable. Palliative resections are only indicated in symptomatic patients.
Keywords: Adrenalectomy; Lymphadenectomy; Oncologic principles; R0 resection; Recurrence.
Similar articles
-
[Surgical strategies for non-metastatic adrenocortical carcinoma].Chirurg. 2018 Jun;89(6):434-439. doi: 10.1007/s00104-017-0582-1. Chirurg. 2018. PMID: 29313128 Review. German.
-
Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature.J Laparoendosc Adv Surg Tech A. 2018 Apr;28(4):408-414. doi: 10.1089/lap.2017.0546. Epub 2018 Jan 10. J Laparoendosc Adv Surg Tech A. 2018. PMID: 29319399 Review.
-
Evaluation, Staging, and Surgical Management for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group.Ann Surg Oncol. 2018 Nov;25(12):3460-3468. doi: 10.1245/s10434-018-6749-2. Epub 2018 Sep 18. Ann Surg Oncol. 2018. PMID: 30229419
-
Minimally invasive adrenal surgery: virtue or vice?Future Oncol. 2018 Feb;14(3):267-276. doi: 10.2217/fon-2017-0420. Epub 2018 Jan 18. Future Oncol. 2018. PMID: 29345155 Review.
-
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.Ann Surg Oncol. 2016 Jan;23(1):126-33. doi: 10.1245/s10434-015-4810-y. Epub 2015 Aug 18. Ann Surg Oncol. 2016. PMID: 26282907 Free PMC article.
Cited by
-
Multidisciplinary team therapy for left giant adrenocortical carcinoma: A case report.World J Clin Cases. 2021 Jul 16;9(20):5737-5743. doi: 10.12998/wjcc.v9.i20.5737. World J Clin Cases. 2021. PMID: 34307633 Free PMC article.
-
Diagnostic and Predictive Recurrence Value of Plasma Fibrinogen in Patients With Adrenocortical Carcinoma.Clin Med Insights Oncol. 2025 Jan 7;19:11795549241271657. doi: 10.1177/11795549241271657. eCollection 2025. Clin Med Insights Oncol. 2025. PMID: 39776667 Free PMC article.
-
Prognostic value of fibrinogen change value in adrenocortical carcinoma patients.Discov Oncol. 2024 Jul 30;15(1):320. doi: 10.1007/s12672-024-01197-5. Discov Oncol. 2024. PMID: 39080085 Free PMC article.
-
SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling.Mol Cell Biochem. 2019 Aug;458(1-2):1-10. doi: 10.1007/s11010-019-03525-8. Epub 2019 Apr 15. Mol Cell Biochem. 2019. PMID: 30989475
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources